In addition to its suppressive activity against CD8+ T cells in ovarian cancer TME [17,32,37], previous studies have demonstrated that MDSC increase the stem cell-like properties of ovarian cancer cells via by producing PGE2 [17], inducing the microRNA101 [32] or CSF2/STAT3 pathway activation [23]. Here, CSF2 is linked to ovarian carcinoma.